Revenues (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue by product are summarized as follows:


	For the Years Ended December 31,
	2021						2020						2019
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
Fumarate(1)	$	1,089.5	$	1,272.8	$	2,362.3	$	2,742.0	$	1,163.4	$	3,905.4	$	3,312.0	$	1,126.2	$	4,438.2
Interferon(2)	983.1		583.0		1,566.1		1,273.5		604.0		1,877.5		1,426.6		675.2		2,101.8
TYSABRI	1,142.2		920.9		2,063.1		1,096.8		849.3		1,946.1		1,041.8		850.4		1,892.2
FAMPYRA	—		105.2		105.2		—		103.1		103.1		—		97.1		97.1
Subtotal: MS	3,214.8		2,881.9		6,096.7		5,112.3		2,719.8		7,832.1		5,780.4		2,748.9		8,529.3

Spinal Muscular Atrophy:
SPINRAZA	587.9		1,317.2		1,905.1		787.8		1,264.3		2,052.1		933.4		1,163.6		2,097.0

Alzheimer's disease:
ADUHELM(3)	3.0		—		3.0		—		—		—		—		—		—

Biosimilars:
BENEPALI	—		498.3		498.3		—		481.6		481.6		—		486.2		486.2
IMRALDI	—		233.4		233.4		—		216.3		216.3		—		184.0		184.0
FLIXABI	—		99.4		99.4		—		97.9		97.9		—		68.1		68.1
Subtotal: Biosimilars	—		831.1		831.1		—		795.8		795.8		—		738.3		738.3

Other:
FUMADERM	—		11.0		11.0		—		12.2		12.2		—		15.2		15.2

Total product revenue	$	3,805.7	$	5,041.2	$	8,846.9	$	5,900.1	$	4,792.1	$	10,692.2	$	6,713.8	$	4,666.0	$	11,379.8

(1) Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.

(2) Interferon includes AVONEX and PLEGRIDY.

(3) In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read Note 18, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, to these consolidated financial statements.

Analysis of change in reserves

An analysis of the change in reserves for discounts and allowances is summarized as follows:


	December 31, 2021
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	141.4	$	1,093.0	$	41.6	$	1,276.0
Current provisions relating to sales in current year	736.7		2,948.7		15.2		3,700.6
Adjustments relating to prior years	(4.0)		(96.1)		(3.3)		(103.4)
Payments/credits relating to sales in current year	(599.3)		(2,283.1)		(0.4)		(2,882.8)
Payments/credits relating to sales in prior years	(137.1)		(902.9)		(15.1)		(1,055.1)
Ending balance	$	137.7	$	759.6	$	38.0	$	935.3


	December 31, 2020
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	131.1	$	1,027.3	$	40.5	$	1,198.9
Current provisions relating to sales in current year	774.7		3,308.8		19.0		4,102.5
Adjustments relating to prior years	(1.0)		(54.0)		1.3		(53.7)
Payments/credits relating to sales in current year	(635.1)		(2,426.1)		—		(3,061.2)
Payments/credits relating to sales in prior years	(128.3)		(763.0)		(19.2)		(910.5)
Ending balance	$	141.4	$	1,093.0	$	41.6	$	1,276.0


	December 31, 2019
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	127.8	$	888.8	$	34.7	$	1,051.3
Current provisions relating to sales in current year	666.2		3,011.5		20.9		3,698.6
Adjustments relating to prior years	0.3		(54.1)		5.5		(48.3)
Payments/credits relating to sales in current year	(535.5)		(2,242.9)		(0.2)		(2,778.6)
Payments/credits relating to sales in prior years	(127.7)		(576.0)		(20.4)		(724.1)
Ending balance	$	131.1	$	1,027.3	$	40.5	$	1,198.9

Total reserves included in consolidated balance sheet

The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:


	As of December 31,
(In millions)	2021		2020
Reduction of accounts receivable	$	133.2	$	195.4
Component of accrued expense and other	802.1		1,080.6
Total revenue-related reserves	$	935.3	$	1,276.0

Revenues from anti-CD20 therapeutic programs

Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.


	For the Years Ended December 31,
(In millions)	2021		2020		2019
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	647.7	$	1,080.2	$	1,542.4
Other revenue from anti-CD20 therapeutic programs	1,010.8		897.6		748.0
Total revenue from anti-CD20 therapeutic programs	$	1,658.5	$	1,977.8	$	2,290.4

Revenue from anti-CD20 therapeutic programs is summarized as follows:


	For the Years Ended December 31,
(In millions)	2021		2020		2019
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	647.7	$	1,080.2	$	1,542.4
Other revenue from anti-CD20 therapeutic programs	1,010.8		897.6		748.0
Total revenue from anti-CD20 therapeutic programs	$	1,658.5	$	1,977.8	$	2,290.4

Other revenues

Other revenue is summarized as follows:


	For the Years Ended December 31,
(In millions)	2021		2020		2019
Revenue from collaborative and other relationships:
Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis	$	20.7	$	20.9	$	106.2
Other revenue from collaborative and other relationships	—		0.7		—
Other royalty and corporate revenue:
Royalty	27.9		33.9		17.0
Other corporate	427.7		719.1		584.5
Total other revenue	$	476.3	$	774.6	$	707.7